| Overview |
| bs-11069R-Cy5 |
| procollagen type 2A Polyclonal Antibody, Cy5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Zebrafish |
| Human, Dog, Cow, Sheep, Pig, Chicken, Rabbit, Guinea Pig |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Collagen II alpha 1 |
| 1-100/1487 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Secreted, Extracellular matrix |
| Collagen II N-terminal propeptide; Collagen II alpha 1; COL2A1; COL2A1 protein; collagen, type II, alpha 1; collagen alpha-1II; type II collagen; alpha-1 type II collagen; alpha1 type II collagen; Col2a1; AOM; Cartilage collagen; COL11A3; Collagen alpha 1II chain precursor; Collagen II alpha 1 polypeptide; Collagen type II alpha 1 primary osteoarthritis spondyloepiphyseal dysplasia congenital; MGC131516; SEDC; Collagen alpha-1II chain; Alpha-1 type II collagen; CO2A1_HUMAN. |
| Collagen type II is the most abundant protein of cartilage matrix. Two isoforms exist and collagen type IIA is involved in early development of cartilage in embryos. The collagen is produced from type II procollagen when two teloterminal propeptides are digested from the precursor and released into the circulation. Procollagen type II N-terminal propeptide is considered a marker of cartilage synthesis and the normal concentration in serum is approximately 30ng/mL. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz